At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ABCL AbCellera Biologics
Trading 08-07 09:48:12 EDT
6.49
-0.04
-0.61%
High6.69Low6.47Vol577.21K
Open6.65D1 Closing6.53Amplitude3.37%
Mkt Cap1.98BTradable Cap1.33BTotal Shares305.26M
T/O3.79MT/O Rate0.28%Tradable Shares205.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

AbCellera Biologics (ABCL) Stock Jumps As Cash Burn Fuels Pipeline Debate
Simply Wall St.  ·  11:36
AbCellera Biologics (ABCL) Stock Jumps As Cash Burn Fuels Pipeline Debate
OmniAb Q2 Revenue Beats Analyst Estimates, Outlook Raised
Reuters  ·  04:40
OmniAb Q2 Revenue Beats Analyst Estimates, Outlook Raised
AbCellera Biologics is Maintained at Buy by Stifel
Dow Jones  ·  08-06 22:24
AbCellera Biologics is Maintained at Buy by Stifel
AbCellera Biologics (ABCL) Gets a Buy from Cantor Fitzgerald
TIPRANKS  ·  08-06 20:00
AbCellera Biologics (ABCL) Gets a Buy from Cantor Fitzgerald
AbCellera Biologics Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-06 07:57
AbCellera Biologics Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
AbCellera Q2 FY26 Net Loss Widens to USD 55.4 Million; Revenue Drops to USD 4.1 Million
Reuters  ·  08-06 04:24
AbCellera Q2 FY26 Net Loss Widens to USD 55.4 Million; Revenue Drops to USD 4.1 Million
AbCellera Biologics Q2 EPS $(0.18) Misses $(0.14) Estimate, Sales $4.050M Miss $7.784M Estimate
Benzinga Earnings  ·  08-06 04:07
AbCellera Biologics Q2 EPS $(0.18) Misses $(0.14) Estimate, Sales $4.050M Miss $7.784M Estimate
AbCellera Q2 Revenue USD 4.1 Million Vs. IBES Estimate USD 7.78 Million
Reuters  ·  08-06 04:06
AbCellera Q2 Revenue USD 4.1 Million Vs. IBES Estimate USD 7.78 Million
Press Release: AbCellera Reports Q2 2026 Business Results
Dow Jones  ·  08-06 04:05
Press Release: AbCellera Reports Q2 2026 Business Results
Abcellera Biologics Inc Expected to Post a Loss of 14 Cents a Share - Earnings Preview
Reuters  ·  08-04
Abcellera Biologics Inc Expected to Post a Loss of 14 Cents a Share - Earnings Preview
Earning Preview: AbCellera Biologics Q2 revenue is expected to increase by 27.21%, and institutional views are cautiously positive
Earnings Agent  ·  07-30
Earning Preview: AbCellera Biologics Q2 revenue is expected to increase by 27.21%, and institutional views are cautiously positive
AbCellera Partners with Vertex to Develop Multispecific T-cell Engagers for Autoimmune Diseases, Other Conditions
Reuters  ·  07-29
AbCellera Partners with Vertex to Develop Multispecific T-cell Engagers for Autoimmune Diseases, Other Conditions
Abcellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
THOMSON REUTERS  ·  07-29
Abcellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
Abcellera Biologics - Vertex to Fund All R&D and Commercialize Antibodies from Collaboration
THOMSON REUTERS  ·  07-29
Abcellera Biologics - Vertex to Fund All R&D and Commercialize Antibodies from Collaboration
Abcellera Biologics - Abccellera to Receive $28 Mln Upfront Plus Milestone Payments and Tiered Royalties
THOMSON REUTERS  ·  07-29
Abcellera Biologics - Abccellera to Receive $28 Mln Upfront Plus Milestone Payments and Tiered Royalties
Does AbCellera’s New Board Appointment Reframe Its Execution Story for Investors in ABCL?
Simply Wall St.  ·  07-20
Does AbCellera’s New Board Appointment Reframe Its Execution Story for Investors in ABCL?
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), AbCellera Biologics (ABCL) and DBV Technologies SA – American (DBVT)
TIPRANKS  ·  07-17
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), AbCellera Biologics (ABCL) and DBV Technologies SA – American (DBVT)
Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS) and AbCellera Biologics (ABCL)
TIPRANKS  ·  07-16
Analysts Offer Insights on Healthcare Companies: Alumis Inc. (ALMS) and AbCellera Biologics (ABCL)
AbCellera Biologics call volume above normal and directionally bullish
TIPRANKS  ·  07-10
AbCellera Biologics call volume above normal and directionally bullish
Press Release: Abcellera to Report Second Quarter 2026 Financial Results on August 5, 2026
Dow Jones  ·  07-08
Press Release: Abcellera to Report Second Quarter 2026 Financial Results on August 5, 2026

Introduction

Company Name.
AbCellera Biologics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Issue price:
--